CA Cancer J Clin. 2025 Jan 16. IF: 503.1Cancer statistics, 2025.www.onlinelibrary.wiley.com/doi/10.3322/caac.21871 CA Cancer J Clin. 2025 Jan 16. IF: 503.1Cancer statistics, 2025: A hinge moment for optimism to morph into hope?www.onlinelibrary.wiley.com/doi/10.3322/caac.21877 Nat Rev Clin Oncol. 2025 Jan 16. IF: 81.1Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.www.nature.com/articles/s41571-024-00984-x Nat Biotechnol. 2025 Jan 16. IF: 33.1Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy.www.nature.com/articles/s41587-024-02535-2 Nat Cancer. 2025 Jan 16. IF: 23.5Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.www.nature.com/articles/s43018-024-00890-2 JAMA Oncol. 2025 Jan 16. IF: 22.5Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.www.jamanetwork.com/journals/jamaoncology/fullarticle/2829035 JAMA Oncol. 2025 Jan 16. IF: 22.5Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review.www.jamanetwork.com/journals/jamaoncology/fullarticle/2829034 Nat Mach Intell. 2025 Jan 16. IF: 18.8A machine learning approach to leveraging electronic health records for enhanced omics analysis.www.nature.com/articles/s42256-024-00974-9 Nat Commun. 2025 Jan 16;16:716. IF: 14.7Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.www.nature.com/articles/s41467-025-56096-2 Nat Commun. 2025 Jan 16;16:682. IF: 14.7Impact of rare non-coding variants on human diseases through alternative polyadenylation outliers.www.nature.com/articles/s41467-024-55407-3 J Clin Invest. 2025 Jan 16;135(2):e187567. IF: 13.3A new twist on superantigen-activated autoimmune disease.www.jci.org/articles/view/187567 Biomaterials. 2025 Jan 14;317:123104. IF: 12.8Remodeling tumor microenvironment by versatile nanoplatform orchestrated mechanotherapy with chemoimmunotherapy to synergistically enhance anticancer efficiency.www.sciencedirect.com/science/article/pii/S0142961225000237 NPJ Digit Med. 2025 Jan 16;8(1):35. IF: 12.4Digital humanistic program to manage premature frailty in young breast cancer survivors with gender perspective.www.nature.com/articles/s41746-025-01439-y Theranostics. 2025 Jan 2;15(4):1456-1477. IF: 12.4Ultrasound-activated erythrocyte membrane-camouflaged Pt (II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death.www.thno.org/v15p1456.htm Theranostics. 2025 Jan 1;15(4):1205-1220. IF: 12.4Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles.www.thno.org/v15p1205.htm Cancer Lett. 2025 Jan 13. IF: 9.1Extending breast cancer screening beyond age 45-64 years in China: a cost-effectiveness analysis.www.sciencedirect.com/science/article/pii/S0304383525000217
